NASDAQ:AVTX Avalo Therapeutics (AVTX) Stock Price, News & Analysis $12.01 -1.23 (-9.29%) Closing price 04:00 PM EasternExtended Trading$11.98 -0.03 (-0.21%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Avalo Therapeutics Stock (NASDAQ:AVTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Avalo Therapeutics alerts:Sign Up Key Stats Today's Range$11.99▼$13.2350-Day Range$13.24▼$20.7552-Week Range$11.99▼$24.27Volume1.65 million shsAverage Volume1.14 million shsMarket Capitalization$644.10 millionP/E RatioN/ADividend YieldN/APrice Target$45.10Consensus RatingModerate Buy Company Overview Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases. The company’s research strategy centers on addressing conditions in which abnormal immune-system activity contributes to inflammation and tissue damage. Avalo’s lead product candidate is AVTX-009, a fully human monoclonal antibody designed to neutralize interleukin-1 beta, a pro-inflammatory cytokine involved in several inflammatory disorders. The company is evaluating AVTX-009 in clinical development for hidradenitis suppurativa, a chronic inflammatory skin condition, and may pursue additional indications in which interleukin-1 beta plays a role. The company was formerly known as Cerecor Inc. and adopted the Avalo Therapeutics name as it shifted its strategic focus toward immunology and inflammation. Avalo is headquartered in Rockville, Maryland, and operates primarily as a research and development organization. Its products remain in clinical development and are not broadly marketed commercial therapies.AI Generated. May Contain Errors. Read More Avalo Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreAVTX MarketRank™: 3.267789030645 of 5 starsAvalo Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 291st out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingAvalo Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on no strong buy ratings, 12 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAvalo Therapeutics has a consensus price target of $45.10, representing about 272.4% upside from its current price of $12.11.Amount of Analyst CoverageAvalo Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Avalo Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Avalo Therapeutics are expected to decrease in the coming year, from ($2.80) to ($2.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avalo Therapeutics is -2.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avalo Therapeutics is -2.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvalo Therapeutics has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Avalo Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted22.26% of the float of Avalo Therapeutics has been sold short.Short Interest Ratio / Days to CoverAvalo Therapeutics has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Avalo Therapeutics has recently decreased by 11.76%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvalo Therapeutics does not currently pay a dividend.Dividend GrowthAvalo Therapeutics does not have a long track record of dividend growth. News and Social Media3.3 / 5News SentimentN/A News SentimentAvalo Therapeutics has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Avalo Therapeutics this week, compared to 3 articles on an average week.Search Interest3 people have searched for AVTX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Avalo Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $415,434.00 in company stock.Percentage Held by Insiders4.46% of the stock of Avalo Therapeutics is held by insiders.Percentage Held by Institutions87.06% of the stock of Avalo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Avalo Therapeutics' insider trading history. Receive AVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AVTX Stock News HeadlinesAvalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)September 29, 2026 | globenewswire.comAvalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 CongressSeptember 23, 2026 | globenewswire.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 13 at 1:00 AM | InvestorPlace (Ad)Insider Selling: Avalo Therapeutics (NASDAQ:AVTX) CFO Sells $202,394.02 in StockSeptember 19, 2026 | insidertrades.comAvalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)September 4, 2026 | globenewswire.comAvalo Therapeutics: Phase 2 Validation Has Created An IL-1β FranchiseSeptember 4, 2026 | seekingalpha.comAvalo Therapeutics to Participate in Upcoming Investor ConferencesSeptember 3, 2026 | globenewswire.comDo Avalo Therapeutics’ (AVTX) Widening Losses But Better EPS Reveal a Turning Point in Strategy?August 11, 2026 | finance.yahoo.comSee More Headlines AVTX Stock Analysis - Frequently Asked Questions How have AVTX shares performed this year? Avalo Therapeutics' stock was trading at $18.16 at the beginning of 2026. Since then, AVTX shares have decreased by 33.3% and is now trading at $12.11. How were Avalo Therapeutics' earnings last quarter? Avalo Therapeutics, Inc. (NASDAQ:AVTX) announced its earnings results on Thursday, August, 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by $0.25. When did Avalo Therapeutics' stock split? Avalo Therapeutics shares reverse split on the morning of Friday, December 29th 2023.The 1-240 reverse split was announced on Friday, December 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. How do I buy shares of Avalo Therapeutics? Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Avalo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avalo Therapeutics investors own include Energy Transfer (ET), Definium Therapeutics (DFTX), Cybin (HELP), Novo Integrated Sciences (NVOS), Palantir Technologies (PLTR), Riot Platforms (RIOT) and T2 Biosystems (TTOO). Company Calendar Last Earnings8/06/2026Today10/13/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (14m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 AVTX's financial health is in the Green zone, according to TradeSmith. AVTX has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AVTX CIK1534120 Webwww.avalotx.com Phone(410) 522-8707FaxN/AEmployees33Year Founded2015Price Target and Rating Average Price Target for Avalo Therapeutics$45.10 High Price Target$60.00 Low Price Target$30.00 Potential Upside/Downside+275.5%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($4.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$78.26 million Net MarginsN/A Pretax Margin-169,766.09% Return on Equity-58.03% Return on Assets-48.22% Debt Debt-to-Equity RatioN/A Current Ratio19.31 Quick Ratio19.31 Sales & Book Value Annual Sales$59 thousand Price / Sales10,916.89 Cash FlowN/A Price / Cash FlowN/A Book Value$4.49 per share Price / Book2.67Miscellaneous Outstanding Shares53,630,000Free Float51,238,000Market Cap$644.10 million OptionableNot Optionable Beta0.68 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:AVTX) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
